

FORM 11

NOTICE OF PROPOSED STOCK OPTION GRANT OR AMENDMENT

Name of Listed Issuer: FSD Pharma Inc. (the "Issuer").

Trading Symbol: HUGE

Date: April 12, 2019

1. New Options Granted:

Date of Grant: April 12, 2019

Name of Optionee	Position (Director/ Officer/ Employee/ Consultant/ Management Company)	Insider Yes or No?	No. of Optioned Shares	Exercise Price	Expiry Date	No. of Options Granted in Past 12 Months
Maryann Adesso	Employee	No	500,000	C\$0.25	April 12, 2024	N/A
John Tokarsky	Employee	No	200,000	C\$0.25	April 12, 2024	N/A
Brandon Suepersadsingh	Employee	No	200,000	C\$0.25	April 12, 2024	N/A
Thi Phuong Hoang	Consultant	No	500,000	C\$0.25	April 12, 2024	N/A

Total Number of optioned shares proposed for acceptance: 1,400,000

2. Other Presently Outstanding Options:

Name of Optionee	No. of Optioned Shares⁽¹⁾	Exercise Price	Original Date of Grant	Expiry Date
Former Director/Officer of FSD Pharma	10,000,000	\$0.022	September 15, 2017	September 15, 2022
Officer of FSD Pharma	20,000,000	\$0.022	September 15, 2017	September 15, 2022
Former optionholder of FV Pharma	1,000,000	\$0.09	February 25, 2018	February 25, 2023
Former optionholder of FV Pharma	2,500,000	\$0.09	March 28, 2018	March 28, 2023
Former optionholder of FV Pharma	3,333,004	\$0.10	April 9, 2018	April 9, 2023
Director/Officer of FSD Pharma	4,000,000	\$0.09	June 12, 2018	June 12, 2023
Director/Officer of FSD Pharma	3,000,000	\$0.13	August 15, 2018	August 15, 2023
Director/Officer of FSD Pharma	40,000,000	\$0.74	September 10, 2018	September 10, 2023
Officer of FSD Pharma	2,000,000	\$0.60	September 15, 2018	September 15, 2023
Consultant	1,000,000	\$0.71	September 26, 2018	September 26, 2023
Director of FSD Pharma	3,000,000	\$0.44	November 12, 2018	November 12, 2023
Consultant of FSD Pharma	250,000	\$0.43	November 15, 2018	November 15, 2023

(1) Set out number of optioned shares for each grant with different terms.

3. Additional Information

- (a) If shareholder approval was required for the grant of options (including prior approval of a stock option plan), state the date that the shareholder meeting approving the grant was or will be held.

No.

- (b) State the date of the news release announcing the grant of options.

N/A. Press release not required.

- (c) State the total issued and outstanding share capital at the date of grant or amendment.

1,388,472,955 Class B Shares issued and outstanding.

- (d) State, as a percentage of the issued and outstanding shares of the Issuer indicated in (c) above, the aggregate number of shares that are subject to incentive stock options, including new options, amended options and other presently outstanding options.

6.49%

- (e) If the new options are being granted pursuant to a stock option plan, state the number of remaining shares reserved for issuance under the plan.

47,364,291

- (f) If the Issuer has completed a public distribution of its securities within 90 days of the date of grant, state the per share price paid by the public investors.

N/A

- (g) Describe the particulars of any proposed material changes in the affairs of the Issuer.

None.

4. Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 11 Notice of Proposed Stock Option Grant or Amendment is true.

Dated: April 12, 2019

Raza Bokhari _____
Name of Director or Senior
Officer

signed ("*Raza Bokhari*") _____
Signature

Interim CEO _____
Official Capacity

**FORM 11 – NOTICE OF PROPOSED STOCK OPTION GRANT
OR AMENDMENT**